We're Bullish on Wide-Moat Amgen
January 02, 2017 at 07:00 AM EST
Five-star-rated Amgen's wide moat is supported by a diverse portfolio that will shield it from biosimilar headwinds.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.